Kocaer, Sinem Burcu

Profile Picture
Profile URL
https://hdl.handle.net/20.500.14365/6973
Name Variants
Koçer, Sinem Burcu
Job Title
Email Address
drsinemburcu@gmail.com
Main Affiliation
09.02. Internal Sciences
Status
Former Staff
Website
ORCID ID
0000-0002-5481-0776
Scopus Author ID
57209243629
Turkish CoHE Profile ID
Google Scholar ID
WoS Researcher ID

Sustainable Development Goals

SDG data is not available
Documents

13

Citations

69

h-index

5

Go to Scopus profile
This researcher does not have a WoS ID.
Scholarly Output

3

Articles

3

Views / Downloads

0/0

Supervised MSc Theses

0

Supervised PhD Theses

0

WoS Citation Count

13

Scopus Citation Count

11

WoS h-index

2

Scopus h-index

1

Patents

0

Projects

0

WoS Citations per Publication

4.33

Scopus Citations per Publication

3.67

Open Access Source

3

Supervised Theses

0

JournalCount
European Journal of Rheumatology1
Kastamonu Medical Journal (KASMEJ)1
Scientific Reports1
Current Page: 1 / 1

Scopus Quartile Distribution

Competency Cloud

GCRIS Competency Cloud

Filters

2023 - 20243
Reset filters

Settings

Scholarly Output Search Results

Now showing 1 - 3 of 3
  • Thumbnail Image
    Article
    Citation - WoS: 11
    Citation - Scopus: 11
    Assessing Safety and Efficacy of Tnfi Treatment in Late Onset Ankylosing Spondylitis: a Turkbio Registry Study
    (Nature portfolio, 2024) Uslu, Sadettin; Gülle, Semih; Şen, Gercek; Cefle, Ayşe; Yılmaz, Sema; Koçer, Sinem Burcu; Yüce İnel, Tuba
    Clinical data on the use of tumour necrosis factor inhibitors (TNFi) in late-onset ankylosing spondylitis (LoAS) are limited. The present study aimed to evaluate efficacy, safety, and treatment adherence associated with the initial use of TNFi therapy in biologic naive patients diagnosed with LoAS. Patients whose age of onset was >= 45 years and < 45 years were classified as having LoAS and YoAS, respectively, based on the age of symptom onset. There were 2573 patients with YoAS and 281 LoAS. Baseline disease activity measures were similar between the groups. No significant differences were seen between the two groups in response to treatment and in remaining on the first TNFi at 6, 12 and 24 months. In the LoAS group, the analysis showed that TNFi discontinuation was linked to VAS pain score (HR 1.04; 95% CI 1.01-1.06). Patient groups had similar rates of adverse events (YoAS: 8.7% vs. LoAS: 11.7%). In both biologic naive LoAS and YoAS patients, the study showed that the initial TNFi therapy was equally effective and safe.
  • Thumbnail Image
    Article
    Citation - WoS: 2
    Matrix Metalloproteinase-2 and -3 Levels in Patients With Behçet's Disease and Implication for the Presence of Vascular Aneurysm or Neurologic Involvement
    (AVES, 2023) Erten, Pınar Talu; Keser, Gökhan; Durusoy, Raika; Kocaer, Sinem Burcu; Aksu, Kenan
    Background: Behçet's disease is a systemic vasculitis affecting both arteries and veins, as well as causing recurrent inflammatory multiorgan disease. Vascular involvement is associated with increased mortality and morbidity. Matrix metalloproteinases are released at sites of inflammation and degrade various components of the extracellular matrix. Increased levels of metalloproteinase-9 and metalloproteinase- 2 have been previously reported in Behçet's disease. Methods: In this cross-sectional study, metalloproteinase-2 and metalloproteinase-3 serum levels were investigated in 103 patients with Behçet's disease and 69 healthy controls, using Invitrogen immunoassay human metalloproteinase-2 and metalloproteinase-3 ELISA kits. Results: Serum metalloproteinase-2 and metalloproteinase-3 levels were significantly higher in the Behçet's disease group compared to healthy controls. Besides, serum metalloproteinase-3 levels were significantly higher in subgroups of Behçet's disease with aneurysmal vascular involvement and with neurological involvement. However, metalloproteinase-2 and metalloproteinase-3 serum levels did not show a positive correlation with disease activity. Conclusion: Metalloproteinase-2 and -3 may contribute to the complex pathogenesis of Behçet's disease. More importantly, the detection of very high serum levels of metalloproteinase-3 may predict the formation of an aneurysm, or possibly the presence of neurological involvement in Behçet's disease and may lead the clinician to make an earlier diagnosis of these complications in young male patients with high risk.
  • Thumbnail Image
    Article
    Concurrent Diagnosis of Sjogren’s Syndrome and Polycthemia Vera: a Rare Co-Existence
    (2023) Ünal, Serkan; Kocaer, Sinem Burcu
    This case report explores the unprecedented concurrent diagnosis of Sjogren’s syndrome (pSS) and polycythemia vera (PV) in a 62-year-old woman presenting with erythrocytosis, classic pSS symptoms, and a positive JAK2-V617F mutation. While autoimmune diseases and hematological malignancies frequently coexist, the combination of PV and pSS has not been previously documented. Despite recurrent phlebotomies for PV, the patient experienced persistent symptoms and elevated inflammatory markers. The case underscores the complexity of managing rare coexisting conditions, emphasizing the importance of considering a broad spectrum of hematological malignancies in primary SS patients. The patient is currently receiving hydroxyurea and hydroxychloroquine with regular follow-ups, shedding light on the challenges associated with the treatment of such unique clinical scenarios. This report contributes to the medical literature by expanding our understanding of potential associations between autoimmune disorders and hematological malignancies beyond conventional patterns.